Background Targeting CTLA-4 is a recent strategic approach in cancer control: blocking
CTLA-4 enhances an antitumor immunity by promoting T-cell activation and cytotoxic T-…

Background Given the phenotypic similarities between rheumatoid arthritis (RA)–associated
interstitial lung disease (ILD) (hereafter, RA-ILD) and idiopathic pulmonary fibrosis, we …

Objectives Adult-onset Still’s disease (AOSD) is a rare systemic autoinflammatory disease;
its management is largely empirical. This is the first clinical study to determine if interleukin (IL)…

Objectives To evaluate the prevalence and type of rheumatic immune-related adverse events
(irAEs) in patients receiving immune checkpoint inhibitors (ICIs), as well as the correlation …

Background Rheumatic and musculoskeletal immune-related adverse events (irAEs) are
observed in about 10% of patients with cancer receiving checkpoint inhibitors (CPIs). Given the …

Objective: To describe cases of lymphoma associated with anti-TNF therapy, identify risk
factors, estimate the incidence and compare the risks for different anti-TNF agents. Methods: A …

Question addressed by the study Methotrexate (MTX) is a key anchor drug for rheumatoid
arthritis (RA) management. Fibrotic interstitial lung disease (ILD) is a common complication of …

Low-dose pulse methotrexate has emerged as one of the most frequently used slow-acting,
symptom-modifying antirheumatic drugs in patients with rheumatoid arthritis (RA) because of …

Increased activity of T follicular helper (Tfh) cells plays a major pathogenic role in systemic
lupus erythematosus (SLE). However, the mechanisms that cause aberrant Tfh cell responses …

OBJECTIVES: The French Society of Rheumatology initiated a large national multicenter,
longitudinal and prospective cohort, the so-called “ESPOIR cohort study” in order to set up …